Boehringer Ingelheim and Eli Lilly Say Diabetes Drug Meets Primary Endpoint
June 25 2018 - 8:54AM
Dow Jones News
By Sarah Coffey
Boehringer Ingelheim and Eli Lilly and Co. (LLY) said Monday
their jointly-tested Type 1 diabetes drug achieved its primary
endpoint in two controlled trials.
The companies said the EASE Phase III program investigated the
use of empagliflozin in combination with insulin therapy in adults
with type 1 diabetes during a 26-week trial.
The full results from the EASE Phase III program will be
presented in October in Berlin.
Empagliflozin isn't currently approved for use in people with
type 1 diabetes, which affects 1.3 million adults in the U.S. and
approximately 30 million adults worldwide. Boehringer Ingelheim and
Lilly said they are exploring regulatory options.
Write to Sarah Coffey at sarah.coffey@wsj.com
(END) Dow Jones Newswires
June 25, 2018 08:39 ET (12:39 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2023 to Sep 2024
